The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases.
This interactive activity features Drs. Howard J. Burstein and Joyce O’Shaughnessy discussing practical aspects of using this class of agents as second-line therapy in HR+/HER2- advanced or metastatic breast cancer.
Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Breast
© 2017 Imedex, LLC.